CA3135157A1 - Medicament for treating cancer - Google Patents

Medicament for treating cancer Download PDF

Info

Publication number
CA3135157A1
CA3135157A1 CA3135157A CA3135157A CA3135157A1 CA 3135157 A1 CA3135157 A1 CA 3135157A1 CA 3135157 A CA3135157 A CA 3135157A CA 3135157 A CA3135157 A CA 3135157A CA 3135157 A1 CA3135157 A1 CA 3135157A1
Authority
CA
Canada
Prior art keywords
antibody
amino acid
acid sequence
seq
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3135157A
Other languages
English (en)
French (fr)
Inventor
Koji Nakamura
Kota Takahashi
Izumi Sakaguchi
Lingyi ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiome Bioscience Inc
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of CA3135157A1 publication Critical patent/CA3135157A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3135157A 2019-04-01 2020-03-31 Medicament for treating cancer Pending CA3135157A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019070120 2019-04-01
JP2019-070120 2019-04-01
PCT/JP2020/014832 WO2020204033A1 (ja) 2019-04-01 2020-03-31 がん治療用医薬

Publications (1)

Publication Number Publication Date
CA3135157A1 true CA3135157A1 (en) 2020-10-08

Family

ID=72668636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3135157A Pending CA3135157A1 (en) 2019-04-01 2020-03-31 Medicament for treating cancer

Country Status (10)

Country Link
US (1) US20220193064A1 (https=)
EP (1) EP3949990A4 (https=)
JP (1) JP7549889B2 (https=)
KR (1) KR20210144767A (https=)
CN (1) CN113660954B (https=)
AU (1) AU2020255907A1 (https=)
CA (1) CA3135157A1 (https=)
IL (1) IL286680A (https=)
TW (1) TWI862564B (https=)
WO (1) WO2020204033A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4226945A4 (en) * 2020-10-05 2024-10-23 Chiome Bioscience, Inc MEDICINES FOR THE TREATMENT OF CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
CN1304046C (zh) * 2004-06-29 2007-03-14 上海人类基因组研究中心 肝癌相关基因dlk1及其应用
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
KR102091871B1 (ko) 2012-07-26 2020-03-20 덴카 주식회사 수지 조성물
ES2665341T3 (es) * 2012-10-03 2018-04-25 Chiome Bioscience Inc. Anticuerpo anti-DLK-1 humana con actividad antitumoral in vivo
SI3579883T1 (sl) * 2017-02-08 2021-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo

Also Published As

Publication number Publication date
EP3949990A1 (en) 2022-02-09
KR20210144767A (ko) 2021-11-30
CN113660954B (zh) 2025-01-14
IL286680A (en) 2021-10-31
AU2020255907A1 (en) 2021-10-28
CN113660954A (zh) 2021-11-16
US20220193064A1 (en) 2022-06-23
JP7549889B2 (ja) 2024-09-12
JPWO2020204033A1 (https=) 2020-10-08
WO2020204033A1 (ja) 2020-10-08
TW202104259A (zh) 2021-02-01
EP3949990A4 (en) 2023-02-08
TWI862564B (zh) 2024-11-21

Similar Documents

Publication Publication Date Title
AU2025203336A9 (en) Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
US9808507B2 (en) Anti-c-Met/anti-Ang2 bispecific antibody
US9127070B2 (en) Anti-DR5 antibodies, polynucleotides and methods
CN118949062A (zh) 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
CN114729035B (zh) 抗cea抗体-依喜替康类似物偶联物及其医药用途
WO2018068758A1 (zh) 抗c-Met抗体-细胞毒性药物偶联物的医药用途
US20250066499A1 (en) Antibody binding to human cd73, preparation method therefor, and use thereof
ES2871598T3 (es) Anticuerpo novedoso contra EGFRvIII y composición que comprende el mismo
US20230398227A1 (en) Medicine for treating cancer
US20220193064A1 (en) Medicament for treating cancer
CN119255825A (zh) 抗-cdh6抗体-药物缀合物的剂量方案
RU2833323C1 (ru) Конъюгат антитела против cea и аналога эксатекана и его фармацевтическое применение
CN118909114A (zh) 一种抗体或其抗原结合片段、抗体药物偶联物及其医药用途
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231128

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250429

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251209

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251209